Autolus Therapeutics (NASDAQ:AUTL) Sees Large Volume Increase – Here’s Why

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) saw unusually-high trading volume on Thursday . Approximately 746,433 shares traded hands during trading, a decline of 44% from the previous session’s volume of 1,344,832 shares.The stock last traded at $4.64 and had previously closed at $4.51.

Autolus Therapeutics Stock Up 3.3 %

The stock has a 50 day moving average of $3.90 and a 200 day moving average of $4.13. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -3.76 and a beta of 2.04. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, analysts expect that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of the business. ProShare Advisors LLC acquired a new stake in shares of Autolus Therapeutics during the 2nd quarter worth approximately $43,000. Bayesian Capital Management LP acquired a new position in shares of Autolus Therapeutics during the first quarter valued at $100,000. Daiwa Securities Group Inc. grew its position in shares of Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in shares of Autolus Therapeutics during the first quarter worth about $108,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Autolus Therapeutics in the 1st quarter worth about $127,000. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.